Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:1556-0864
-
Container-title:Journal of Thoracic Oncology
-
language:en
-
Short-container-title:Journal of Thoracic Oncology
Author:
Parikh KaushalORCID,
Dimou Anastasios,
Leventakos Konstantinos,
Mansfield Aaron S.,
Shanshal Mohamed,
Wan Yin,
Lin Huamao M.,
Vincent Sylvie,
Elliott Jennifer,
Bonta Ioana R.